CRISPR-Cas9 delivery to hard-to-transfect cells via membrane deformation

Virus-free gene editing possible at chromosomes through stretching cells in a micropost array, even for hard-to-transfect cells. The CRISPR (clustered regularly interspaced short palindromic repeats)–Cas (CRISPR-associated) nuclease system represents an efficient tool for genome editing and gene function analysis. It consists of two components: single-guide RNA (sgRNA) and the enzyme Cas9. Typical sgRNA and Cas9 intracellular delivery techniques are limited by their reliance on cell type and exogenous materials as well as their toxic effects on cells (for example, electroporation). We introduce and optimize a microfluidic membrane deformation method to deliver sgRNA and Cas9 into different cell types and achieve successful genome editing. This approach uses rapid cell mechanical deformation to generate transient membrane holes to enable delivery of biomaterials in the medium. We achieved high delivery efficiency of different macromolecules into different cell types, including hard-to-transfect lymphoma cells and embryonic stem cells, while maintaining high cell viability. With the advantages of broad applicability across different cell types, particularly hard-to-transfect cells, and flexibility of application, this method could potentially enable new avenues of biomedical research and gene targeting therapy such as mutation correction of disease genes through combination of the CRISPR-Cas9–mediated knockin system.

[1]  Long-chuan Yu,et al.  Microinjection as a tool of mechanical delivery. , 2008, Current opinion in biotechnology.

[2]  David T. Curiel,et al.  Engineering targeted viral vectors for gene therapy , 2007, Nature Reviews Genetics.

[3]  Yu-Chen Hu Baculoviral vectors for gene delivery: a review. , 2008, Current gene therapy.

[4]  Suresh Ramakrishna,et al.  Gene disruption by cell-penetrating peptide-mediated delivery of Cas9 protein and guide RNA , 2014, Genome research.

[5]  Zabner,et al.  Cationic lipids used in gene transfer. , 1997, Advanced drug delivery reviews.

[6]  Kai Zhang,et al.  Block-Cell-Printing for live single-cell printing , 2014, Proceedings of the National Academy of Sciences.

[7]  M. Morris,et al.  Twenty years of cell-penetrating peptides: from molecular mechanisms to therapeutics , 2009, British journal of pharmacology.

[8]  Junjie Chen,et al.  Tumor Suppressor P53 Binding Protein 1 (53bp1) Is Involved in DNA Damage–Signaling Pathways , 2001, The Journal of cell biology.

[9]  W. Mark Saltzman,et al.  Synthetic DNA delivery systems , 2000, Nature Biotechnology.

[10]  E. Lander,et al.  Development and Applications of CRISPR-Cas 9 for Genome Engineering , 2015 .

[11]  Ping Zhu,et al.  Correction of a genetic disease by CRISPR-Cas9-mediated gene editing in mouse spermatogonial stem cells , 2014, Cell Research.

[12]  Daesik Kim,et al.  Highly efficient RNA-guided genome editing in human cells via delivery of purified Cas9 ribonucleoproteins , 2014, Genome research.

[13]  Le Cong,et al.  Multiplex Genome Engineering Using CRISPR/Cas Systems , 2013, Science.

[14]  Junjie Chen,et al.  Akt regulates TPP1 homodimerization and telomere protection , 2013, Aging cell.

[15]  Peijing Zhang,et al.  Deubiquitination and stabilization of PTEN by USP13 , 2013, Nature Cell Biology.

[16]  E. Lander,et al.  Development and Applications of CRISPR-Cas9 for Genome Engineering , 2014, Cell.

[17]  James E. DiCarlo,et al.  RNA-Guided Human Genome Engineering via Cas9 , 2013, Science.

[18]  Neville E. Sanjana,et al.  Genome-Scale CRISPR-Cas9 Knockout Screening in Human Cells , 2014, Science.

[19]  E. Lander,et al.  Genetic Screens in Human Cells Using the CRISPR-Cas9 System , 2013, Science.

[20]  Stéphanie Panier,et al.  Double-strand break repair: 53BP1 comes into focus , 2013, Nature Reviews Molecular Cell Biology.

[21]  K. Nakashiro,et al.  Knockdown of Akt isoforms by RNA silencing suppresses the growth of human prostate cancer cells in vitro and in vivo. , 2010, Biochemical and biophysical research communications.

[22]  Hao Yin,et al.  CRISPR-mediated direct mutation of cancer genes in the mouse liver , 2014, Nature.

[23]  Shuming Nie,et al.  Cell-penetrating quantum dots based on multivalent and endosome-disrupting surface coatings. , 2007, Journal of the American Chemical Society.

[24]  Hans Clevers,et al.  Functional repair of CFTR by CRISPR/Cas9 in intestinal stem cell organoids of cystic fibrosis patients. , 2013, Cell stem cell.

[25]  Shulin Li,et al.  Electroporation gene therapy: new developments in vivo and in vitro. , 2004, Current gene therapy.

[26]  P. Gregory,et al.  CRISPR technology for gene therapy , 2014, Nature Medicine.

[27]  Facundo D. Batista,et al.  RIF1 Is Essential for 53BP1-Dependent Nonhomologous End Joining and Suppression of DNA Double-Strand Break Resection , 2013, Molecular cell.

[28]  Francesco Stellacci,et al.  Surface-structure-regulated cell-membrane penetration by monolayer-protected nanoparticles. , 2008, Nature materials.

[29]  Hao Yin,et al.  Genome editing with Cas9 in adult mice corrects a disease mutation and phenotype , 2014, Nature Biotechnology.

[30]  H. C. Mastwijk,et al.  Electroporation of cells in microfluidic devices: a review , 2006, Analytical and bioanalytical chemistry.

[31]  Robert Langer,et al.  A vector-free microfluidic platform for intracellular delivery , 2013, Proceedings of the National Academy of Sciences.

[32]  Wei Tang,et al.  Correction of a genetic disease in mouse via use of CRISPR-Cas9. , 2013, Cell stem cell.